This web page provides frequently asked questions for rules on prescribing buprenorphine and other and other medications for opioid use disorder (MOUD), following 2023 policy updates.
This web page provides frequently asked questions regarding the 2023 Medication Access and Training Expansion (MATE) Act which requires new or renewing DEA licensees to have completed a total of at least eight hours of training on opioid or other substance use disorders and the appropriate treatment of pain.
This letter announces details on the 2023 Medication Access and Training Expansion (MATE) Act which requires new or renewing DEA licensees to have completed a total of at least eight hours of training on opioid or other substance use disorders and the appropriate treatment of pain.
This web page provides frequently asked questions regarding the 2023 Consolidated Appropriations Act, which eliminates the X-waiver (DATA-Waiver) and increases accessibility of medication-assisted treatment (MAT).
This guidance document provides information regarding issuance of updated DEA registration certificates to reflect Congress’s elimination of the X-waiver (DATA-Waiver) in the Consolidated Appropriations Act of 2023, increasing accessibility of medication-assisted treatment (MAT).
This letter announces details on Congress's elimination of the X-waiver (DATA-Waiver) to increase buprenorphine accessibility in the Consolidated Appropriations Act of 2023, increasing accessibility of medication-assisted treatment (MAT).
This webinar discusses trends in THC potency and delivery and their systems, marijuana risks for developing fetal brain systems and adolescent brain, and what to do with this information.
This on-demand webinar reviews research on 12-step mutual help groups for people seeking to recovery from addiction and discusses the mechanisms through which 12-step groups affect members.